<DOC>
	<DOCNO>NCT01671943</DOCNO>
	<brief_summary>The purpose study evaluate clinical feasibility safety ICESENSE3TM cryotherapy system ablation small malignant invasive breast tumor .</brief_summary>
	<brief_title>Cryotherapy Breast Cancer Trial</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Unifocal primary invasive ductal breast carcinoma diagnose core needle biopsy . Patients contralateral disease remain eligible . Note : Results ER , PR , HER2/neu must obtain preregistration needle core biopsy material . Tumor size â‰¤ 2.0 cm great diameter measure breast ultrasound , MRI mammogram . The large dimension measure used determine eligibility . Tumor enhancement MRI Tumor &lt; 25 % intraductal component aggregate . Nonpregnant nonlactating patient . Patients childbearing potential must negative serum urine pregnancy test . NOTE : Perimenopausal woman must amenorrheic &gt; 12 month consider childbearing potential . Adequate breast size safe cryoablation . Patients breast small allow safe cryoablation eligible minimal thickness breast tissue lend cryoablation . NOTE : The minimal distance tumor margin breast skin analogous surgical margin lumpectomy . Patients multifocal and/or multicentric ipsilateral breast cancer , multifocal calcification , evidence excessive DCIS . History rotational vacuum assist core biopsy , en bloc open surgical biopsy and/or lumpectomy diagnosis/treatment index breast cancer . Prior plan neoadjuvant chemotherapy breast cancer . Patients thrombocytopenia coagulation abnormality</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>small malignant invasive breast tumor</keyword>
</DOC>